Project Grant R42DA062250
Award Date
4/15/25
Completion Date
3/31/26
Dollars Obligated
$400K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This $586,936 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of a low-cost, disposable urine test strip for rapidly quantifying substance use disorder (SUD) medication drugs and their metabolites. The project aims to create a field-deployable, point-of-use diagnostic solution that enables fast, quantitative detection of drugs like buprenorphine, methadone, and naltrexone in patients'...
The National Institute on Drug Abuse (NIDA) awarded Labsys LLC a $643,948 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a wearable continuous drug monitoring device for opioid use disorders (CDM-MOUD). The goal is to create a low-cost, painless patch that can monitor medication levels in the interstitial fluid, providing real-time insights into the effectiveness of treatment protocols. In Phase I, the project will focus on engineering an alpha...
The National Institute on Drug Abuse (NIDA) awarded a $386,452 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant, with a performance period from April 1, 2025 to March 31, 2026, aims to support the development of rapid fingerstick diagnostics for the detection of opioid and stimulant use disorders. This aligns with NIDA's broader research focus on advancing scientific...
The National Institute on Drug Abuse (NIDA) awarded Tenvos Inc., a minority-owned and woman-owned small business, a $800,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a software-based medical device for remotely detecting opioid use through voice analysis. The proposed solution will integrate into a smartphone app, enabling patients to test for opioid use from home and securely transmit results to clinicians without requiring in-person visits. This...
This Project Grant award from the National Institute on Drug Abuse (NIDA), as part of the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,076,018 to Dynamicare Health Inc. to conduct a randomized clinical trial for their digital therapeutic product DCH-003. DCH-003 is designed to deliver contingency management and other evidence-based interventions for the treatment of stimulant use disorder (STUD), an area with few FDA-approved treatments available. The study will compare...
The National Institute on Drug Abuse (NIDA), through its Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $399,589 Project Grant to Resilient Lifescience, Inc. The purpose of this grant, awarded on Sep 15, 2024, is to develop a wearable medical device to detect opioid overdose. The project is expected to be completed by Aug 31, 2025. The Drug Use and Addiction Research Programs support a wide range of research activities related to substance use disorders, addiction, and related...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $320,000 to Fannin Partners LLC, a Houston-based biotech company, to develop a novel PDE4B inhibitor drug called 11H for the treatment of stimulant use disorders (STUD). The key innovation is the selective inhibition of an inflammatory pathway in the brain while reducing adverse events associated with currently available non-selective...
This Project Grant award of $1,594,478 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to develop digital biomarkers and phenotypes of craving patterns during medication for opioid use disorder (MOUD) treatment. The primary awardee, the University of Massachusetts Medical School, will conduct a 60-day observational study with 300 participants initiating MOUD treatment. Continuous wearable sensor data will...
The National Institute on Drug Abuse (NIDA) awarded a $800,000 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to Biosensics LLC for the development and clinical validation of ODALERT, a wearable device designed to detect and alert users and first responders of potential opioid overdoses. The key products and services to be delivered under this 1-year grant include: 1) Completing the development of the ODALERT sensor, optimizing the battery, and deploying...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279) provides $318,257 to Cari Health, Inc. to develop a therapeutic monitoring system (TMS) for remote medication compliance tracking of methadone treatment for opioid use disorder (OUD). The key products and services to be delivered include: 1) Integrating an electrochemical sensor, microneedle array, and data pipeline into a prototype wearable...